Brief: Supernus Pharmaceuticals Q3 Revenue USD 153.9 Million Vs. IBES Estimate USD 143.4 Million
08/11/2023 21:06
Nov 08 (Reuters) - Supernus Pharmaceuticals Q3 adjusted operating earnings USD 37.3 million. * Q3 operating earnings USD 8.1 million
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing